SIR,
We are grateful to Dr Armstrong for sharing his views and concerns about our recent paper that elicited patients’ preferences for osteoporosis drug treatment using a cross-European discrete-choice experiment (DCE).
First, the correspondent questioned the use of DCE in the area of osteoporosis therapy. Although the application of DCEs within healthcare is relatively new, DCEs are nowadays increasingly used to elicit preferences for various healthcare conditions and purposes. Previous DCEs were already conducted in osteoporosis, suggesting that respondents were able to discriminate between medication attributes and that a DCE could be suitable in the area of osteoporosis. Our study confirms this finding. [...]

Additional Metadata
Persistent URL dx.doi.org/10.1093/rheumatology/kex430, hdl.handle.net/1765/105161
Journal Rheumatology (United Kingdom)
Citation
Hiligsmann, M, Dellaert, B.G.C, Watson, V, & Boonen, A. (2018). Comment on: Patients' preferences for anti-osteoporosis drug treatment: A cross-european discrete choice experiment: Reply. Rheumatology (United Kingdom), 57(3), 584–585. doi:10.1093/rheumatology/kex430